Bangying Su

Corporate Officer/Principal at Washington University in St. Louis

Consumer Services

Health Technology

Profile

Bangying Su is currently a Principal at Washington University in St. Louis and a Principal at The University of Alabama.
Previously, Dr. Su worked as a Scientist at Dynamis Therapeutics, Inc. Dr. Su completed their undergraduate degree at Peking University.

Bangying Su active positions

Companies	Position	Start
Washington University in St. Louis	Corporate Officer/Principal	2010-01-24
The University of Alabama	Corporate Officer/Principal	2010-01-24

All active positions of Bangying Su

Former positions of Bangying Su

Companies	Position	End
Dynamis Therapeutics, Inc. Dynamis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dynamis Therapeutics, Inc. operates as a holding company with interests in developing pharmaceuticals and diagnostics. It operates through its subsidiaries Dynamis Pharmaceuticals, Inc. and Dynamis Skin Science. The firm's product DYN 15, a drug candidate that prevents the formation of 3DG, a reactive sugar, as well as decreases the levels of key cytokines that are stimulated in chronic inflammations. The company was founded by Annette M. Tobia on May 21, 1997 and is headquartered in Jenkintown, PA.	Corporate Officer/Principal	-

See the detail of Bangying Su's experience

Training of Bangying Su

Peking University

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Bangying Su's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Dynamis Therapeutics, Inc. Dynamis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dynamis Therapeutics, Inc. operates as a holding company with interests in developing pharmaceuticals and diagnostics. It operates through its subsidiaries Dynamis Pharmaceuticals, Inc. and Dynamis Skin Science. The firm's product DYN 15, a drug candidate that prevents the formation of 3DG, a reactive sugar, as well as decreases the levels of key cytokines that are stimulated in chronic inflammations. The company was founded by Annette M. Tobia on May 21, 1997 and is headquartered in Jenkintown, PA.	Health Technology